Literature DB >> 19127532

Sensory loss in multifocal motor neuropathy: a clinical and electrophysiological study.

Virginie Lambrecq1, Elsa Krim, Marie Rouanet-Larrivière, Alain Lagueny.   

Abstract

Some patients fulfilling the criteria for the diagnosis of multifocal motor neuropathy with conduction block (MMN-CB) at the onset of disease may subsequently develop a sensory loss associated with electrophysiological sensory abnormalities. The latter could represent an overlap between MMN-CB and multifocal acquired demyelinating sensory and motor (MADSAM) neuropathy. The objective was to specify the features of MMN-CB with sensory loss (MMN-CB-Se). Five patients in a series of 11 consecutive patients who fulfilled the criteria of the American Association of Neuromuscular and Electrodiagnostic Medicine for MMN-CB at the first examination and were treated periodically with intravenous immunoglobulin (IVIg) developed sensory loss in the course of the disease. In these five patients we compared the clinical, laboratory, and electrophysiological features found after the development of sensory loss with those at the first examination. The mean time to appearance of objective sensory signs was 7.2 years. In three of the five patients the sensory loss was preceded by intermittent paresthesias in the same nerve territories as the motor involvement. The most frequent electrophysiological abnormality was amplitude reduction of sensory nerve action potentials. There were no bilateral or symmetrical clinical and electrophysiological sensory abnormalities. Anti-GM1 IgM antibodies were positive in four patients. MMN-CB-Se could be an overlap between MMN-CB and MADSAM. It shares the distribution of the sensory disorders encountered in MADSAM, but it is closer to MMN-CB on clinical and therapeutic levels. Study of more patients would be useful to classify this subgroup more accurately.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19127532     DOI: 10.1002/mus.21163

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  8 in total

Review 1.  Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies.

Authors:  Lotte Vlam; W-Ludo van der Pol; Elisabeth A Cats; Dirk C Straver; Sanneke Piepers; Hessel Franssen; Leonard H van den Berg
Journal:  Nat Rev Neurol       Date:  2011-11-22       Impact factor: 42.937

Review 2.  Diagnosis and treatment of chronic acquired demyelinating polyneuropathies.

Authors:  Norman Latov
Journal:  Nat Rev Neurol       Date:  2014-07-01       Impact factor: 42.937

Review 3.  Immune-mediated neuropathies.

Authors:  Bernd C Kieseier; Emily K Mathey; Claudia Sommer; Hans-Peter Hartung
Journal:  Nat Rev Dis Primers       Date:  2018-10-11       Impact factor: 52.329

Review 4.  Immunoglobulin for multifocal motor neuropathy.

Authors:  Stephen Keddie; Filip Eftimov; Leonard H van den Berg; Ruth Brassington; Rob J de Haan; Ivo N van Schaik
Journal:  Cochrane Database Syst Rev       Date:  2022-01-11

5.  Do patients having a decrease in SNAP amplitude during the course of MMN present with a different condition?

Authors:  Emilien Delmont; Charles Benaïm; Mael Launay; Sabrina Sacconi; Marie-Hélène Soriani; Claude Desnuelle
Journal:  J Neurol       Date:  2009-07-30       Impact factor: 4.849

Review 6.  Multifocal motor neuropathy, multifocal acquired demyelinating sensory and motor neuropathy, and other chronic acquired demyelinating polyneuropathy variants.

Authors:  Mazen M Dimachkie; Richard J Barohn; Jonathan Katz
Journal:  Neurol Clin       Date:  2013-02-16       Impact factor: 3.806

7.  Corneal confocal microscopy in chronic inflammatory demyelinating polyneuropathy.

Authors:  Mark Stettner; Lena Hinrichs; Rainer Guthoff; Silja Bairov; Ioannis N Petropoulos; Clemens Warnke; Hans-Peter Hartung; Rayaz A Malik; Bernd C Kieseier
Journal:  Ann Clin Transl Neurol       Date:  2015-12-28       Impact factor: 4.511

Review 8.  Multifocal motor neuropathy: a review of pathogenesis, diagnosis, and treatment.

Authors:  Victoria H Lawson; W David Arnold
Journal:  Neuropsychiatr Dis Treat       Date:  2014-04-05       Impact factor: 2.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.